1. Home
  2. LEGN vs MMSI Comparison

LEGN vs MMSI Comparison

Compare LEGN & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • MMSI
  • Stock Information
  • Founded
  • LEGN 2014
  • MMSI 1987
  • Country
  • LEGN United States
  • MMSI United States
  • Employees
  • LEGN N/A
  • MMSI N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • MMSI Medical/Dental Instruments
  • Sector
  • LEGN Health Care
  • MMSI Health Care
  • Exchange
  • LEGN Nasdaq
  • MMSI Nasdaq
  • Market Cap
  • LEGN 7.0B
  • MMSI 5.6B
  • IPO Year
  • LEGN 2020
  • MMSI 1990
  • Fundamental
  • Price
  • LEGN $39.70
  • MMSI $103.16
  • Analyst Decision
  • LEGN Strong Buy
  • MMSI Strong Buy
  • Analyst Count
  • LEGN 12
  • MMSI 10
  • Target Price
  • LEGN $79.50
  • MMSI $109.80
  • AVG Volume (30 Days)
  • LEGN 976.3K
  • MMSI 466.6K
  • Earning Date
  • LEGN 03-10-2025
  • MMSI 02-25-2025
  • Dividend Yield
  • LEGN N/A
  • MMSI N/A
  • EPS Growth
  • LEGN N/A
  • MMSI 19.39
  • EPS
  • LEGN N/A
  • MMSI 2.05
  • Revenue
  • LEGN $520,183,000.00
  • MMSI $1,325,871,000.00
  • Revenue This Year
  • LEGN $121.13
  • MMSI $9.75
  • Revenue Next Year
  • LEGN $65.25
  • MMSI $9.13
  • P/E Ratio
  • LEGN N/A
  • MMSI $50.32
  • Revenue Growth
  • LEGN 122.96
  • MMSI 8.12
  • 52 Week Low
  • LEGN $30.17
  • MMSI $70.70
  • 52 Week High
  • LEGN $70.13
  • MMSI $111.45
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 64.82
  • MMSI 41.15
  • Support Level
  • LEGN $34.36
  • MMSI $106.87
  • Resistance Level
  • LEGN $36.39
  • MMSI $110.10
  • Average True Range (ATR)
  • LEGN 1.67
  • MMSI 2.22
  • MACD
  • LEGN 0.34
  • MMSI -0.80
  • Stochastic Oscillator
  • LEGN 94.68
  • MMSI 1.44

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About MMSI Merit Medical Systems Inc.

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.

Share on Social Networks: